KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV Stock Report

Market Cap: US$446.2m

KalVista Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:KALV Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Nov 24BuyUS$12,000,000Frazier Life Sciences Management, LPCompany1,200,000US$10.00
28 Mar 24SellUS$14,905,154TCG Crossover Management, LLCCompany1,355,014US$11.00
20 Feb 24BuyUS$999,988Frazier Life Sciences Management, LPCompany65,573US$15.25
16 Feb 24SellUS$13,151,726TCG Crossover Management, LLCCompany877,125US$16.22
14 Feb 24SellUS$598,661Christopher YeaIndividual39,886US$15.01
14 Feb 24SellUS$422,827Edward FeenerIndividual28,171US$15.01
14 Feb 24SellUS$875,883Thomas CrockettIndividual58,356US$15.01
14 Feb 24SellUS$613,205Benjamin PalleikoIndividual40,855US$15.01
08 Feb 24BuyUS$1,257,829VR Adviser, LLCCompany86,048US$14.74
30 Jan 24BuyUS$1,274,793VR Adviser, LLCCompany88,099US$14.47
25 Jan 24BuyUS$89,492VR Adviser, LLCCompany7,030US$12.73
24 Jan 24BuyUS$1,241,685VR Adviser, LLCCompany99,129US$12.55
19 Jan 24BuyUS$1,801,602VR Adviser, LLCCompany143,605US$12.60
16 Jan 24BuyUS$333,779VR Adviser, LLCCompany26,246US$12.73
10 Jan 24BuyUS$1,726,457VR Adviser, LLCCompany137,700US$12.67

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KALV?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders746,8111.46%
Hedge Funds8,328,90416.2%
VC/PE Firms11,137,59821.7%
Institutions31,079,83660.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43%.

Top Shareholders

Top 25 shareholders own 93.42% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.7%
VR Adviser, LLC
6,249,731US$56.4m0%2.83%
9.89%
Frazier Life Sciences Management, LP
4,887,867US$44.1m32.5%1.68%
8.76%
Suvretta Capital Management, LLC
4,328,904US$39.1m3.27%1.42%
8.74%
Tang Capital Management, LLC
4,321,547US$39.0m2.43%2.81%
8.09%
Vestal Point Capital, LP
4,000,000US$36.1m73.9%2.89%
6.83%
Capital Research and Management Company
3,374,064US$30.5m4.54%no data
6.2%
BlackRock, Inc.
3,062,319US$27.7m3.98%no data
4.35%
The Vanguard Group, Inc.
2,150,527US$19.4m8.03%no data
3.22%
Tavistock Life Sciences
1,590,000US$14.4m0%0.99%
3.01%
Emerald Advisers, LLC
1,486,968US$13.4m26.7%0.28%
2.87%
Adage Capital Management, L.P.
1,419,792US$12.8m-30.7%0.02%
2.63%
Great Point Partners, LLC
1,299,503US$11.7m-2.92%4.38%
2.57%
State Street Global Advisors, Inc.
1,271,609US$11.5m68.1%no data
1.81%
BioImpact Capital LLC
896,915US$8.1m1.7%1.36%
1.68%
Geode Capital Management, LLC
830,984US$7.5m3.07%no data
1.46%
Dafna Capital Management, LLC
723,678US$6.5m-10.3%1.7%
1.23%
Woodline Partners LP
608,253US$5.5m304%0.05%
1.23%
Dimensional Fund Advisors LP
607,036US$5.5m13.5%no data
1.16%
Silverarc Capital Management, LLC
574,558US$5.2m2.44%1.2%
1.13%
Saturn V Capital Management LP
556,489US$5.0m-50.7%2.12%
0.87%
Schroder Investment Management Limited
431,232US$3.9m-7.86%no data
0.77%
Medical Strategy GmbH, Asset Management Arm
382,666US$3.5m0%0.21%
0.77%
Northern Trust Global Investments
379,375US$3.4m14%no data
0.76%
Jefferies Financial Group Inc.,Asset Management Arm
375,000US$3.4m114%0.06%
0.72%
First Turn Management, LLC
355,000US$3.2m-66.5%0.54%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 05:46
End of Day Share Price 2025/01/06 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KalVista Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
null nullBTIG
Charles DuncanCantor Fitzgerald & Co.